The financials
Teladoc Health, Inc. by the numbers
Teladoc Health, Inc. (TDOC) reported revenue of $614M in Q1 2026 (quarter ended March 31, 2026), down 2.5% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $64M. For the full year FY2025, revenue was $2.53B (−1.5% year on year) and net income −$200M. Its largest product in 2026-Q1 was Subscription Access Fees at $485M, 79% of the disclosed total, just ahead of Other at 21%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $614M | $629M | −2.5% |
| Gross profit | $416M | $433M | −3.8% |
| Operating income | −$62M | −$121M | n/a |
| Net income | −$64M | −$93M | n/a |
| Diluted EPS | −$0.36 | −$0.53 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Subscription Access Fees | $485M | 79% |
| Other | $129M | 21% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $613.8M (-2.0%)
Other grew +25% year on yearSubscription Access Fees -7.8% year on year
Segment Latestquarter on quarteryear on year
- Subscription Access Fees$484.7M$484.7MQoQ -7.0%year on year -7.8%-7.0%-7.8%
- Other$129.2M$129.2MQoQ +22%year on year +25%+22%+25%
Health Information Services
Ranks #5 of 14 by Smart Score